- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04617782
Crossover Pharmacokinetic (PK) Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers
A Phase 1, Open-Label, 3-Period, Randomized, Crossover Pharmacokinetic Study to Evaluate the Steady-State Pharmacokinetics of 5 mg and 10 mg Corplex™ Donepezil Transdermal Delivery Systems Compared to 10 mg Oral Administration of Aricept® in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening Period:
Subjects will undergo a Screening Period up to 28 days prior to entering the Treatment Phase.
Treatment Phase consisting of 3 Treatment periods with 3 Treatments A, B, C.
Treatment Period 1: All Subjects will receive Treatment A; 5 mg/day Donepezil Transdermal Delivery System (TDS); 1-week wear and applied for 5 consecutive weeks.
Treatment Periods 2 and 3: Subjects will be randomized (by gender) to receive either sequences of Treatments B-C or Treatments C-B.
Treatment B: 10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks Treatment C: 10 mg/day Aricept® donepezil tablet administered daily (QD) for 5 weeks.
Blood samples for pharmacokinetics and safety assessments will be collected during the Treatment Phase.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78217
- Worldwide Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females.
- Subject's Body Mass Index (BMI) must be between 18 and 32 kg/m2 (inclusive).
- Subject must be continuous non-smokers.
- Subject must have a Fitzpatrick skin type of I, II or III.
Exclusion Criteria:
- History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
After resting seated for at least 3 minutes, subjects should be excluded from the study with the following vital signs at Screening
- systolic blood pressure outside the range of 90-145 mmHg, or
- diastolic blood pressure outside the range of 50-90 mmHg, or
- resting heart rate outside the range of 40-100 beats per minute.
- Has an isolated ALT ≥1.5x the ULN or AST ≥1.5x the ULN at Screening; or both ALT and AST exceeding the ULN.
- Estimated creatinine clearance at screening <70 mL/min/1.73 m2.
- Prolonged corrected QTcF on screening ECG (≥450 ms for both females and males).
- History or presence of excessive hairy skin on application sites as deemed by the Investigator to potentially interfere with patch adhesion or drug absorption.
- History or presence of significant skin damage, diffuse skin diseases-, scars, tattoos on the application sites or other skin disturbances as deemed by the Investigator to potentially interfere with drug absorption or skin tolerability assessments
- Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration.
- Has participated in another clinical trial within 30 days prior to Day -1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
|
Transdermal Delivery System
|
Experimental: Treatment B
10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
|
Transdermal Delivery System
|
Active Comparator: Treatment C
10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steady State Bioequivalence of 10 mg/day donepezil
Time Frame: 35 days of Treatment of each comparator
|
To evaluate steady-state donepezil plasma exposure following once-weekly treatments with 10 mg/day Corplex™ Donepezil TDS compared to once-daily oral administration of 10 mg Aricept®
|
35 days of Treatment of each comparator
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-P-20003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Donepezil TDS
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
Corium, Inc.CompletedSkin Irritation | SensitizationUnited States
-
Corium, Inc.CompletedAlzheimer's DiseaseUnited States
-
Corium, Inc.Completed
-
Corium, Inc.CompletedAlzheimer's DiseaseUnited States
-
Senju USA, Inc.Completed
-
Senju USA, Inc.Completed
-
AcclarentCompletedOtitis MediaUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)CompletedPeer Review, ResearchUnited States
-
U.S. Army Medical Research and Development CommandActive, not recruiting